Short answer
Aquestive Therapeutics, Inc. (AQST) filed its Q2 2026 10-Q quarterly report on Aug 11, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $14M (up 38.1% year over year) with net income of −$23M.
Q2 2026 key financials · XBRL
- Revenue
- $14M
- +38.1% YoY · −4.3% QoQ
- Net income
- −$23M
- −68.8% YoY · −183.8% QoQ
- Operating margin
- -59.5%
- EPS (diluted)
- −$0.18
- −38.5% YoY · −157.1% QoQ
Source: XBRL data from the Aquestive Therapeutics, Inc. (AQST) Q2 2026 10-Q on SEC EDGAR. USD.
Aquestive Therapeutics, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- Newly disclosed insider-trading risk: Rule 10b5-1 plans covering 132,992 shares adopted by the Chief Development and Commercial Officers
- Financial risk: May 12, 2026 Oaktree credit agreement secured by a security agreement
- Compliance risk: Omitted credit-agreement provisions may limit visibility into lender obligations
- Regulatory risk: Executive share sales depend on Rule 10b5-1(c) conditions and specified plan terms
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Aquestive Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.